Abstract: Objective:To evaluate therapeutic efficacy and adverse reactions of synchronous chemoradiotherapy combined with gamma knife therapy for pelvic lymph node metastasis of cervical cancers. Methods:Data of42cervical cancer patients who suffered from residual pelvic lymph node metastasis and received concurrent chemoradiotherapy were retrospectively analyzed. Intensity-modu -lated radiotherapy was used in the treatment. The prescribed doses of planning target volume and pelvic metastasized lymph node of the planned gross tumor volume were 50.4 Gy/28F and 59.92Gy/28F, respectively. The combined internal irradiation dose was 6 Gy/6 F. Concurrent chemotherapy was administered with 40mg/m2·w cisplatin. Three months after chemoradiotherapy was completed, the pa -tients with residual pelvic positive lymph node received additional dose ranging from 10Gy to15Gy at three or four fractions by using a gamma knife. Results: Near-term efficacy was 83.3% (35/42) in three months. Local control rates were 88.1% (37/42), 83.3% (35/42), and 76.2% (32/42) in 6, 9, and 12months, respectively. The1- and 2-year survival rates were 77.5% (31/40) and70.0% (28/40), re -spectively. The incidence rates of radiation enteritis, proctitis, cystitis, gut toxicity, and neutrocytopenia were 11 .9% (5/42), 38.1% (16/42), 7.1% (3/42), 90.5% (38/42), and 85.7% (36/42), respectively, and the majority of these conditions were classified as grades I and II. Conclusion:Synchronous chemoradiotherapy combined with gamma knife therapy is an effective and feasible treatment method for pelvic lymph node metastasis of cervical cancer; this method exhibits a minimal adverse reaction.